Lost in translation: the toll-like receptor 7 induced pharmacological challenge model of the skin
Assil, S.

Citation

Assil, S. (2025, January 10). *Lost in translation: the toll-like receptor 7 induced pharmacological challenge model of the skin*. Retrieved from https://hdl.handle.net/1887/4175409

LIST OF PUBLICATIONS

Van der Meulen L.W.J., Bergmans M.E., Assil S., Abdisalaam I., *Rijneveld R., et al.* No clinical improvement after short term topical anti-staphylococcal endolysin SA.100 therapy in patients with mild to moderate atopic dermatitis; results of a randomized, vehicle-controlled trial. *Submitted.*

Assil S., van Noort J.A., Rissmann R., Moerland M., Niemeyer-Van der Kolk T. Lost in translation: A Commentary on TLR7 agonistic response between mice and humans. *Submitted.*

Assil S.*, van Noort J.A.*, Ronner M.N., Osse M., *Pot I., et al.* (2024). Extending the IMQ model: deep characterization of the human TLR7 response for early drug development. *Inflammation,* doi.org/10.1007/s10753-024-02127-x.

Meertens M.A., Luijf T., van Lindonk E.A., Soegiharto R., *Assil S., et al.* (2023). Age and fast initial response predict omalizumab retreatment in chronic urticaria. The Journal of Allergy and Clinical Immunology: In Practice, 11(11). doi.org/10.1016/j.jaip.2023.07.030.

Assil S., Buters T.P., Hameeteman P.W., Hallard C., *Treijtel N., et al.* (2023). Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model. *Frontiers in Immunology*, 14. doi.org/10.3389/fimmu.2023.1197650.

Assil S.*, Niemeyer- Van der Kolk T.*, Rijsbergen M., Buters T.P., *Klaassen E.S., et al.* (2019). Omiganan enhances imiquimod-induced inflammatory response in a human skin challenge model. *Clinical and Translational Science.* Doi.org/10.1111/cts.12741.

Assil S., Rissmann R., and Van Doorn M.B.A. (2019) Pharmacological Challenge Models in Clinical Drug Developmental Programs. *Inflammation-From Molecular Basis to Clinical Outcomes. IntechOpen.* doi.org/10.5772/intechopen.85352.

Van der Kolk T., Assil S., Rijneveld R., Klaassen E.S., *Feiss G. et al. (2018).* Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development. *Clinical Translational Science.* doi.org/10.1111/cts.12563

CURRICULUM VITAE

Salma Assil was born on 5 april 1995, in Moscow. She completed her gymnasium education at Sint- Maartenscollege in Voorburg in 2013 and started her bachelor's degree 'Bio-Farmaceutische Wetenschappen' at the Leiden University the same year. After graduating with her bachelor's degree in 2016, she pursued a master's degree in 'Bio-Pharmaceutical Sciences' specializing in the track 'Science based business'. During her master's program, she completed two internships: the first at the Centre for Human Drug Research (CHDR) in Leiden and a six-month marketing internship at Sanofi. After obtaining her master's degree in December 2018, Salma advanced her scientific career as PhD student and Clinical Scientist at CHDR and LACDR, under the supervision of prof. dr. Robert Rissmann, Dr. Martijn van Doorn and Dr. Tessa Niemeyer-Van der Kolk. In 2023, Salma was promoted to the role of Clinical Study Manager at the CHDR. During her PhD, Salma fell for the charms of the fellow PhD student and ski instructor, Wouter Bakker, with whom she is now engaged. Salma lives with Wouter and Lucas in Sassenheim.